Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Intangibles (2016 - 2025)

Historic Intangibles for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $31.7 million.

  • Lineage Cell Therapeutics' Intangibles fell 5207.35% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.7 million, marking a year-over-year decrease of 5207.35%. This contributed to the annual value of $46.5 million for FY2024, which is 4.72% down from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Intangibles stood at $31.7 million, which was down 5207.35% from $31.7 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Intangibles' 5-year high stood at $66.1 million during Q1 2021, with a 5-year trough of $31.7 million in Q2 2025.
  • Moreover, its 5-year median value for Intangibles was $46.5 million (2024), whereas its average is $52.2 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Intangibles surged by 4224.3% in 2023, and later tumbled by 5207.35% in 2025.
  • Lineage Cell Therapeutics' Intangibles (Quarter) stood at $66.1 million in 2021, then changed by 0.0% to $66.1 million in 2022, then decreased by 29.6% to $46.6 million in 2023, then dropped by 0.05% to $46.5 million in 2024, then crashed by 31.89% to $31.7 million in 2025.
  • Its last three reported values are $31.7 million in Q3 2025, $31.7 million for Q2 2025, and $46.5 million during Q1 2025.